Molecular Partners AG
Company Profile
Business description
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Contact
Wagistrasse 14
Schlieren
Zurich8952
CHET: +41 447557700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
159
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,439.10 | 73.40 | 0.88% |
| CAC 40 | 7,593.87 | 38.00 | 0.50% |
| DAX 40 | 22,496.98 | 71.15 | 0.32% |
| Dow JONES (US) | 40,752.96 | 83.60 | 0.21% |
| FTSE 100 | 8,496.80 | 1.95 | 0.02% |
| HKSE | 22,493.17 | 373.76 | 1.69% |
| NASDAQ | 17,710.74 | 264.40 | 1.52% |
| Nikkei 225 | 36,717.49 | 265.19 | 0.73% |
| NZX 50 Index | 12,311.33 | 162.73 | 1.34% |
| S&P 500 | 5,604.14 | 35.08 | 0.63% |
| S&P/ASX 200 | 8,218.50 | 72.90 | 0.89% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |